ITB-MED
PrivateLast Round
VC Round
Apr 4, 2018
Company Overview
ITB-MED operates in Healthcare & Life Sciences and is based in Stockholm. Its latest recorded funding round was a VC Round in April 2018.
ITB-MED is a biotechnology company that develops immunomodulatory biologics, including its lead candidate Siplizumab (TCD601), for the treatment of transplantation, autoimmunity, and neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ITB-MED Comparables
Compare ITB-MED with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Quell Therapeutics | 78% | |
| TolerogenixX GmbH | 76% | |
| Bristol Myers Squibb | 69% |
For institutional investors. Book with your work email.
ITB-MED Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 4, 2018
$67M round led by Pablo Legorreta
For institutional investors. Book with your work email.
ITB-MED Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ITB-MED's valuation, stock price, and market status.
Is ITB-MED a public or private company?
ITB-MED is a private company.
What is the current stock price of ITB-MED?
ITB-MED is a private company, so its shares have no public market price. Caplight tracks ITB-MED's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ITB-MED worth (valuation)?
Valuation information for ITB-MED is not publicly available.
Can I buy ITB-MED stock?
ITB-MED shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ITB-MED's last funding round?
ITB-MED's most recent funding round was VC Round on April 4, 2018.
Who are the main investors in ITB-MED?
Investor information for ITB-MED is not publicly disclosed.
Will ITB-MED IPO soon?
No public IPO plans have been announced for ITB-MED.
How can I track ITB-MED secondary market activity?
Caplight tracks bids, offers, and trades in ITB-MED's shares on secondary markets.